Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum Toxin for Radiation-related Xerostomia in Head and Neck Cancer
NCT06530524Phase 2Not yet recruiting
- Sponsor
- Jewish General Hospital
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in xerostomia comparing Placebo with OnabotulinumtoxinA (2 arms). Primary endpoint: Xerostomia-related quality of life at 12 months. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
xerostomia
Beyond the preview
Go deeper on NCT06530524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530524.